Dr Jay Edelberg Discusses Results of Alirocumab by Race and Ethnicity
December 21st 2017Trial results have shown that alirocumab (Praluent) is safe and effective across patient populations, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.
Read More
Dr Mary Ann Bauman Outlines the New Hypertension Guidelines Awareness Campaign
November 26th 2017As the American Heart Association (AHA) rolls out its new hypertension guidelines, it has developed a 2-pronged approach for how to get the message out and drive awareness about the new guidelines and recommended lifestyle changes, explained Mary Ann Bauman, MD, of AHA.
Read More
Dr Robert Carey Outlines the New Blood Pressure Classifications
November 16th 2017The new hypertension guidelines made major changes to the classification of blood pressure, in general, and changed the name of one category to convey more importance, explained Robert Carey, MD, MACP, professor of medicine and dean emeritus at the University of Virginia.
Read More
Dr Jay Edelberg on Safety, Efficacy of Praluent and Remaining Payment Challenges
November 16th 2017New results on alirocumab (Praluent) show that it is safe and effective for patients with familial hypercholesterolemia (FH), and yet these patients are faced with an unprecedented situation where some payers refuse to pay for the therapy, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.
Read More
What Happens When Medication Adherence Improves, but Outcomes Don't Change?
November 15th 2017The findings, presented at the 2017 American Heart Association Scientific Sessions, suggest that a "precision medicine" approach to tailoring adherence strategies to individual patients may be needed, according to the study's lead author.
Read More
Dr Niteesh Choudhry Highlights Outcomes From an Intervention to Promote Medication Adherence
November 15th 2017Recent results from a team-based, scalable intervention to promote medication adherence highlighted that the relationship between adherence and clinical outcomes is not always clear cut, said Niteesh Choudhry, MD, PhD, associate professor at Harvard Medical School.
Read More
Dr Andre Lamy Discusses Cost Savings Seen in the COMPASS Trial
November 15th 2017The outcomes in the COMPASS trial of rivaroxaban to treat patients with peripheral artery disease have been very positive, and a new analysis has looked at the cost impact of bringing the drug to market, explained Andre Lamy, MD, MHSc, FRSC, a cardiac surgeon with the Population Health Research Institute in Hamilton, Ontario, Canada.
Read More
Dr Paul Whelton Outlines the Importance of Out-of-Office Blood Pressure Measurements
November 14th 2017The time a patient is in a doctor's office represents a very small window of the body normally, which makes out-of-office blood pressure measurements important to confirm diagnosis of hypertension, explained Paul Whelton, MD, MSc, professor of global public health at Tulane University.
Read More
Dr Eliot Brinton: EMPA-REG Big Step Forward in Type 2 Diabetes Treatment
November 14th 2017The EMPA-REG trial has been a big step forward for clinicians being able to put patients with type 2 diabetes onto treatment that also reduces cardiovascular disease risk, which is the primary cause of death in these patients, explained Eliot A. Brinton, MD, FAHA, FNLA, president of the Utah Lipid Center.
Read More
Dr Roxana Mehran Discusses the Outcomes of the PIONEER AF Study
December 1st 2016The PIONEER AF-PCI trial studied bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention with 3 different treatments. The study found that a rivaroxaban (Xarelto)-based strategy had a significant reduction of bleeding complications, explained Roxana Mehran, MD, FACC, FACP, professor of medicine and director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine.
Read More
Cutting Sugary Drink Sales by 20% Through Education, Not a Tax
November 13th 2016The results from a wide-ranging public health effort in Howard County, Maryland, show a decline in sugary beverage consumption nearly on par with early results from Berkeley, California, which passed the nation's first soda tax.
Read More